Promethera Biosciences to Present Preclinical Data on NASH-Fibrosis Program at 2016 AASLD Meeting

Mont-Saint-Guibert, Belgium, November 8, 2016 – Promethera Biosciences SA, a world-leading cell therapy and regenerative medicine company targeting liver diseases, today announced that preclinical NASH-Fibrosis data from its HepaStem program will be presented in a late-breaking poster presentation at The Liver Meeting® 2016, the 67th Annual Meeting of the American Association for the Study of Liver Disease (AASLD), being held from November 11-15, 2016, in Boston, Massachusetts.

The results demonstrate the beneficial effect of HepaStem in a NASH mouse model and provide further details on the underlying mechanisms of action. HepaStem is a cell suspension constituted of heterologous human adult liver-derived mesenchymal stem cells isolated from normal adult human liver tissue. HepaStem treatment has been shown to be safe in a phase I/II study in 20 pediatric patients.
Poster Information:
Title: “Clinical-grade human liver mesenchymal stem cells for the treatment of NASH- Fibrosis through immunomodulation” – Abstract #LB-29

Session: Late-Breaking Poster Session

Poster presentation: November 13, 2016, 8:00 am – 5.30 pm EDT (2:00 pm – 11.30 pm CET)
Promethera will announce the complete results presented at the meeting after the presentation.